COHORT Aktie

 

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors...

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45....

Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study....

SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist (“GLP-1 RA”), which demonstrated consistent weight reduction across five multiple ascending dose (“MAD”) cohorts over four weeks and encouraging tolerability even when reaching 400 mg QD in the highest dosing cohort after only a single one-week titration step. Together, these findings provide encouraging early evidence of BMF-650's clinical activity, sustained weight-reduction trajectory, and, importantly, it's tolerability....

LAEKNA-B (02105.HK) disclosed that it is actively seeking partners with global capabilities to accelerate the global development and commercialization of its self-developed weight control candidate drug LAE102.The company said it recently completed the 24-week monotherapy study for the low-dose cohort of LAE102. The data were co......

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed to the next planned dose level of RC220 in combination with osimertinib.......

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced positive top-line results from Cohort 1 (gluten challenge) of ANB033's Phase 1b trial in celiac disease (CeD). ANB033, an investigational, subcutaneously administered CD122 antagonist, is designed to inhibit the signaling of both IL-15 and IL-2 on immune cells....

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT....

SYDNEY, Oct. 8, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the......

Federal data show Duke alumni earning a bigger median income four years after graduation than any other majors from any school. It's a small cohort....

Clarity Pharmaceuticals hits SECuRE main-group recruitment target, advancing its prostate cancer therapy trial as Phase III planning gets underway....

Two consecutive trading sessions erased roughly 74.86% of Fractyl Health's share value after the Company reported REMAIN-1 Midpoint Cohort data that the lawsuit alleges corrected earlier statements about Revita DMR's weight-maintenance efficacy. NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Levi......

Inaugural cohort will receive mentorship from impact executives, professional development funding, and access to Net Impact's national network EL CERRITO, CA / ACCESS Newswire / October 7, 2026 / N......

- Dubai Business Associates welcomes young professionals from 15 countries as international talent continues to choose Dubai DUBAI, UAE, Oct. 7, 2026/PRNewswire/ -- Dubai Business Associates (DBA) has welcomed 23 emerging professionals from 15 countries to its 12th cohort, selected from......

First patient enrolled in cohort combining bexobrutideg with venetoclax...

SALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- ARUP Laboratories has been selected for the second cohort of challenge projects in Utah's Redtail AI Factory with its project, "Scaling EventHorizon with Redtail: A Foundation Model for Clinical Flow Cytometry." The award will provide......

DES MOINES, Iowa, Oct. 6, 2026 /PRNewswire/ -- BioSpace, the leader in biopharma news and careers, has revealed the 2026 cohort for its second 40 Under 40 list. BioSpace's 40 Under 40 honors exemplary biotech and pharma professionals who have distinguished themselves in their companies......

Pharmability today announced that the first patient has been dosed in the company's first-in-human Phase Ib clinical trial of TIR-C in atopic dermatitis. Enrolment of the first cohort has also been completed. The study will generate the first clinical data on TIR-C, with a primary focus on safety and local tolerability. [Pharmability-first-patient-dosed-phase-Ib-atopic-dermatitis.png] STOCKHOLM, SWEDEN, October 6, 2026 – The first cohort comprises eight participants enrolled at the clinical site in Sweden. Once all participants in the cohort have completed treatment, safety data will be...

CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the Company's GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and patients with hepatic encephalopathy (HE)....

Buy now pay later lenders are rallying as a group, and Affirm Holdings (NASDAQ:AFRM) leads a cohort climbing in step while the wider financials sector barely moves. Affirm stock is changing hands at $74.47 in midday trading, up 5%. This advance stretches from the largest pure play in the space all the way to a […]...